Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system.


Journal

Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690

Informations de publication

Date de publication:
03 2020
Historique:
received: 25 07 2019
revised: 29 10 2019
accepted: 05 11 2019
pubmed: 24 11 2019
medline: 9 6 2021
entrez: 24 11 2019
Statut: ppublish

Résumé

High-dimensional mass cytometry data potentially enable a comprehensive characterization of immune cells. In order to positively affect clinical trials and translational clinical research, this advanced technology needs to demonstrate a high reproducibility of results across multiple sites for both peripheral blood mononuclear cells (PBMC) and whole blood preparations. A dry 30-marker broad immunophenotyping panel and customized automated analysis software were recently engineered and are commercially available as the Fluidigm® Maxpar® Direct™ Immune Profiling Assay™. In this study, seven sites received whole blood and six sites received PBMC samples from single donors over a 2-week interval. Each site labeled replicate samples and acquired data on Helios™ instruments using an assay-specific acquisition template. All acquired sample files were then automatically analyzed by Maxpar Pathsetter™ software. A cleanup step eliminated debris, dead cells, aggregates, and normalization beads. The second step automatically enumerated 37 immune cell populations and performed label intensity assessments on all 30 markers. The inter-site reproducibility of the 37 quantified cell populations had consistent population frequencies, with an average %CV of 14.4% for whole blood and 17.7% for PBMC. The dry reagent coupled with automated data analysis is not only convenient but also provides a high degree of reproducibility within and among multiple test sites resulting in a comprehensive yet practical solution for deep immune phenotyping.

Identifiants

pubmed: 31758746
doi: 10.1002/cyto.b.21858
pmc: PMC7543682
mid: NIHMS1614520
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

146-160

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2019 International Clinical Cytometry Society.

Références

Sci Rep. 2016 Feb 10;6:20686
pubmed: 26861911
Cytometry A. 2016 Jun;89(6):601-7
pubmed: 27061608
Cytometry B Clin Cytom. 2012 Sep;82(5):313-8
pubmed: 22730140
J Immunol Methods. 2018 Feb;453:37-43
pubmed: 29174717
Blood. 2013 Jul 18;122(3):456-7
pubmed: 23869076
J Immunol Methods. 2013 Nov 29;397(1-2):8-17
pubmed: 23954473
Methods Mol Biol. 2018;1678:11-36
pubmed: 29071673
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
J Immunol. 2017 Mar 15;198(6):2479-2488
pubmed: 28179497
Cytometry B Clin Cytom. 2012 Sep;82(5):319-24
pubmed: 22566361
Nat Immunol. 2003 Sep;4(9):835-42
pubmed: 12942084
Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):227-35
pubmed: 25529112
Anal Chem. 2008 Apr 1;80(7):2539-47
pubmed: 18318509
Int J Lab Hematol. 2013 Oct;35(5):548-54
pubmed: 23521723
Cytometry A. 2015 Jul;87(7):646-60
pubmed: 26012929

Auteurs

Charles Bruce Bagwell (CB)

Verity Software House, Topsham, Maine.

Benjamin Hunsberger (B)

Verity Software House, Topsham, Maine.

Beth Hill (B)

Verity Software House, Topsham, Maine.

Donald Herbert (D)

Verity Software House, Topsham, Maine.

Christopher Bray (C)

Verity Software House, Topsham, Maine.

Thirumahal Selvanantham (T)

Fluidigm Canada Inc., Markham, Ontario, Canada.

Stephen Li (S)

Fluidigm Canada Inc., Markham, Ontario, Canada.

Jose C Villasboas (JC)

Mayo Clinic, Immune Monitoring Core, Rochester, MN.

Kevin Pavelko (K)

Mayo Clinic, Immune Monitoring Core, Rochester, MN.

Michael Strausbauch (M)

Mayo Clinic, Immune Monitoring Core, Rochester, MN.

Adeeb Rahman (A)

Icahn School of Medicine at Mount Sinai, New York, New York.

Gregory Kelly (G)

Icahn School of Medicine at Mount Sinai, New York, New York.

Shahab Asgharzadeh (S)

Children's Hospital Los Angeles, Los Angeles, California.

Azucena Gomez-Cabrero (A)

Children's Hospital Los Angeles, Los Angeles, California.

Gregory Behbehani (G)

Ohio State University, Columbus, Ohio.

Hsiaochi Chang (H)

Ohio State University, Columbus, Ohio.

Justin Lyberger (J)

Ohio State University, Columbus, Ohio.

Ruth Montgomery (R)

Yale School of Medicine, New Haven, Connecticut.

Yujiao Zhao (Y)

Yale School of Medicine, New Haven, Connecticut.

Margaret Inokuma (M)

Verity Software House, Topsham, Maine.

Ofir Goldberger (O)

Fluidigm Corporation, San Francisco, California.

Greg Stelzer (G)

Fluidigm Corporation, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH